Mural Oncology (MURA) Competitors $2.70 +0.28 (+11.57%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.69 -0.01 (-0.37%) As of 04/17/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MURA vs. CRBP, RANI, TCRX, ACOG, CNTX, GNTA, MNOV, IZTC, ABOS, and IFRXShould you be buying Mural Oncology stock or one of its competitors? The main competitors of Mural Oncology include Corbus Pharmaceuticals (CRBP), Rani Therapeutics (RANI), TScan Therapeutics (TCRX), Alpha Cognition (ACOG), Context Therapeutics (CNTX), Genenta Science (GNTA), MediciNova (MNOV), Invizyne Technologies (IZTC), Acumen Pharmaceuticals (ABOS), and InflaRx (IFRX). These companies are all part of the "pharmaceutical products" industry. Mural Oncology vs. Corbus Pharmaceuticals Rani Therapeutics TScan Therapeutics Alpha Cognition Context Therapeutics Genenta Science MediciNova Invizyne Technologies Acumen Pharmaceuticals InflaRx Corbus Pharmaceuticals (NASDAQ:CRBP) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership. Which has stronger valuation & earnings, CRBP or MURA? Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorbus PharmaceuticalsN/AN/A-$44.60M-$3.66-1.65Mural OncologyN/AN/A-$207.45M-$7.58-0.36 Do insiders and institutionals hold more shares of CRBP or MURA? 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 80.2% of Mural Oncology shares are held by institutional investors. 4.0% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of Mural Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to CRBP or MURA? In the previous week, Mural Oncology had 8 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 11 mentions for Mural Oncology and 3 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 0.67 beat Mural Oncology's score of -0.12 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mural Oncology 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community favor CRBP or MURA? Corbus Pharmaceuticals received 447 more outperform votes than Mural Oncology when rated by MarketBeat users. However, 80.00% of users gave Mural Oncology an outperform vote while only 67.01% of users gave Corbus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCorbus PharmaceuticalsOutperform Votes45567.01% Underperform Votes22432.99% Mural OncologyOutperform Votes880.00% Underperform Votes220.00% Is CRBP or MURA more profitable? Corbus Pharmaceuticals' return on equity of -42.28% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Corbus PharmaceuticalsN/A -42.28% -32.92% Mural Oncology N/A -70.10%-61.30% Do analysts prefer CRBP or MURA? Corbus Pharmaceuticals presently has a consensus price target of $59.13, suggesting a potential upside of 880.51%. Mural Oncology has a consensus price target of $13.00, suggesting a potential upside of 381.48%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Corbus Pharmaceuticals is more favorable than Mural Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more risk and volatility, CRBP or MURA? Corbus Pharmaceuticals has a beta of 3.12, indicating that its share price is 212% more volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 5.28, indicating that its share price is 428% more volatile than the S&P 500. SummaryCorbus Pharmaceuticals beats Mural Oncology on 11 of the 16 factors compared between the two stocks. Get Mural Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for MURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MURA vs. The Competition Export to ExcelMetricMural OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.52M$6.46B$5.31B$7.35BDividend YieldN/A3.21%5.45%4.34%P/E Ratio-0.306.9521.9417.82Price / SalesN/A231.01380.6697.73Price / CashN/A65.6738.2534.64Price / Book0.175.936.453.98Net Income-$207.45M$143.22M$3.22B$247.81M7 Day Performance162.14%4.28%5.85%3.19%1 Month Performance-30.23%-13.11%-9.62%-7.70%1 Year Performance-24.37%-8.51%11.79%1.49% Mural Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MURAMural Oncology2.5808 of 5 stars$2.70+11.6%$13.00+381.5%-24.4%$46.52MN/A-0.30119Options VolumeGap UpHigh Trading VolumeCRBPCorbus Pharmaceuticals3.1207 of 5 stars$5.80-4.0%$59.13+919.4%-84.6%$70.95MN/A-1.2440RANIRani Therapeutics1.6502 of 5 stars$1.23+3.4%$12.33+902.7%-83.5%$70.47M$1.03M-1.16110Gap UpTCRXTScan Therapeutics2.5149 of 5 stars$1.24flat$9.33+652.7%-78.9%$70.17M$2.82M-1.17100ACOGAlpha Cognition1.7916 of 5 stars$4.83+10.3%$20.00+314.1%N/A$70.09MN/A-1.89N/APositive NewsCNTXContext Therapeutics1.7046 of 5 stars$0.85+9.6%$6.17+621.4%-36.1%$69.98MN/A-0.947GNTAGenenta Science1.5176 of 5 stars$3.79+3.8%$25.00+559.6%-0.5%$69.32MN/A0.007MNOVMediciNova1.5152 of 5 stars$1.40+1.4%$9.00+542.9%+4.3%$68.66M$1M-6.0910Analyst ForecastNews CoverageGap UpIZTCInvizyne TechnologiesN/A$10.90-7.4%N/AN/A$68.15MN/A0.00N/ANews CoverageABOSAcumen Pharmaceuticals3.2 of 5 stars$1.10-0.9%$7.33+566.7%-71.4%$67.24MN/A-0.8020Positive NewsIFRXInflaRx2.1906 of 5 stars$0.98+6.0%$9.00+818.5%-21.5%$65.78M$165,789.00-0.9160Short Interest ↑ Related Companies and Tools Related Companies Corbus Pharmaceuticals Competitors Rani Therapeutics Competitors TScan Therapeutics Competitors Alpha Cognition Competitors Context Therapeutics Competitors Genenta Science Competitors MediciNova Competitors Invizyne Technologies Competitors Acumen Pharmaceuticals Competitors InflaRx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MURA) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MURA Stock Free MURA Stock Alerts